What alternative medications can be used instead of mesalamine for mild‑to‑moderate ulcerative colitis?

Mesalamine Alternatives for Mild-to-Moderate Ulcerative Colitis

For patients with mild-to-moderate ulcerative colitis who cannot use mesalamine, sulfasalazine (2-4 g/day) or diazo-bonded 5-ASA agents (balsalazide, olsalazine) are the primary alternatives, though they have higher intolerance rates. 1

First-Line Alternatives to Mesalamine

Diazo-Bonded 5-ASA Agents

• Balsalazide and olsalazine are effective alternatives that deliver 5-ASA to the colon through azo-bond cleavage 1
• These agents are recommended at the same level as standard-dose mesalamine for extensive mild-moderate UC 1
• Olsalazine may cause secretory diarrhea as a notable side effect 1
• Dosing: Balsalazide 2-6.75 g/day (equivalent to 0.7-2.4 g/day 5-ASA); Olsalazine 2-3 g/day (equivalent to 1.6-2.4 g/day 5-ASA) 1

Sulfasalazine

• Sulfasalazine 2-4 g/day is particularly appropriate for patients already in remission on this agent or those with prominent arthritic symptoms, especially when cost is prohibitive 1
• The AGA guidelines note this comes with a higher rate of intolerance compared to mesalamine 1
• Sulfasalazine consists of 5-ASA linked to sulfapyridine, with the sulfapyridine component responsible for most adverse effects 1

For Mesalamine-Refractory Disease

Corticosteroids

• For patients refractory to optimized oral and rectal 5-ASA therapy, the AGA suggests adding either oral prednisone or budesonide MMX 1
• This recommendation applies regardless of disease extent 1
• Budesonide MMX (9 mg once daily) has demonstrated efficacy specifically in mesalamine-refractory mild-to-moderate UC, achieving combined clinical and endoscopic remission in 13.0% vs 7.5% with placebo 2
• Budesonide MMX showed superior endoscopic remission rates (20.0% vs 12.3%) and histological healing (27.0% vs 17.5%) compared to placebo in mesalamine-refractory patients 2

Rectal Corticosteroids

• For patients with proctosigmoiditis or proctitis who are intolerant of or refractory to mesalamine suppositories, rectal corticosteroid therapy is suggested over no therapy 1
• Rectal corticosteroid foam preparations may be selected by patients who prioritize avoiding difficulties with mesalamine enemas over maximal effectiveness 1

Advanced Therapies (Beyond Traditional Alternatives)

When 5-ASA alternatives and corticosteroids prove inadequate, escalation to advanced therapies becomes necessary:

• Anti-TNF agents (infliximab, adalimumab, golimumab) are established for moderate-to-severe UC 3, 4
• Vedolizumab (anti-integrin α4β7) has proven efficacy for induction and maintenance of remission 5, 6, 4
• JAK inhibitors (tofacitinib, upadacitinib) show dose-related efficacy, with upadacitinib demonstrating particularly high clinical remission rates in both bio-naive and bio-experienced patients 6, 7
• Sphingosine-1-phosphate receptor modulators (ozanimod, etrasimod) represent newer oral options 3, 7
• IL-12/23 inhibitors (mirizikizumab) offer another mechanism of action 7

Important Clinical Caveats

What NOT to Use

• The AGA makes no recommendation for probiotics, curcumin, or fecal microbiota transplantation outside of clinical trials for mild-moderate UC 1
• Using these unproven therapies risks delaying effective treatment with potential for worsening symptoms or complications 1

Monitoring Requirements

• All 5-ASA alternatives require periodic renal function monitoring 1, 8
• Rare but serious adverse effects include interstitial nephritis and idiosyncratic worsening of colitis 1

Disease-Specific Considerations

• For proctitis specifically, mesalamine suppositories remain strongly recommended even if oral mesalamine is not tolerated 1
• For extensive or left-sided disease, combining oral and rectal therapies is preferred before switching agents entirely 1